All lobbying filings

INDIGO HILL STRATEGIES

Lobbying for SICK CELLS · National Sickle Cell Advocacy

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$30,000

What the client paid this registrant for the period.

Client based in

Illinois

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Budget/Appropriations

Labor/HHS Appropriations H.R 1796/ S. 735 - Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 H.R. 5178/ S.721 - Sickle Cell Disease Comprehensive Care Act

Health Issues

H.R 1796/ S. 735 - Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 H.R. 5178/ S.721 - Sickle Cell Disease Comprehensive Care Act

Bills named in this filing 4

H.R. 1796
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
S. 735
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
H.R. 5178
Sickle Cell Disease Comprehensive Care Act
S. 721
Sickle Cell Disease Comprehensive Care Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.